Evolution of the Average Target: DiaSorin S.p.A.

Evolution of the Target Price: DiaSorin S.p.A.

Changes in Analyst Recommendations: DiaSorin S.p.A.

387d6.5LmNWGDh9rG7nfFF5YWqQGA9Av3VBXvGgPLGwRf9Kks.hfS4NxOpr5zK86F9lNbnMixnR5GTdC-3yrr_h0aRWjO7iu9sL5TCyfXQwQ~af0ead7acac1225c16d9500508d64e35
06-11 Piper Sandler Begins Diasorin Coverage with Neutral Rating MT
05-21 DiaSorin: Soft start, loaded H2 Alphavalue
05-11 DiaSorin: Tough quarter, but margins beat and guidance stood firm Alphavalue
05-11 Buy-side prevails on MIB; DiaSorin shows strength AN
04-09 UBS Downgrades DiaSorin to Neutral Rating, Cuts PT MT
03-24 Invest Securities Downgrades DiaSorin to Neutral Rating, Cuts PT MT
03-23 DiaSorin: Lackluster 2026 guidance and execution uncertainty spook investors Alphavalue
03-23 Mediobanca Downgrades Diasorin to Neutral Rating, Cuts PT MT
03-23 Equita SIM Downgrades Diasorin to Hold, Cuts PT MT
12-31 AlphaValue/Baader Europe Lowers DiaSorin's PT, Keeps at Buy MT
12-30 AlphaValue/Baader Europe Cuts Diasorin Price Target, Forecasts Amid Challenges to Near-term Earnings MT
12-30 DiaSorin trims outlook amid market headwinds Alphavalue
11-27 Intesa Sanpaolo Upgrades Diasorin to Buy, Cuts PT MT
11-07 Deutsche Bank Downgrades Diasorin to Hold, Cuts PT MT
11-06 DiaSorin share slump after Q3 earnings miss Alphavalue
11-06 Banca Akros Downgrades Diasorin to Accumulate, Cuts PT MT
31/10/25 DiaSorin receives FDA authorization for Covid and influenza detection kit AN
12/09/25 DiaSorin: The sky looks clearer for DiaSorin Alphavalue
27/08/25 JP Morgan Begins Diasorin's Coverage at Underweight MT
26/08/25 Morgan Stanley Upgrades Diasorin to Overweight, Lifts PT MT
14/08/25 RBC Capital Upgrades DiaSorin to Outperform MT
01/08/25 DiaSorin: Decent Q2 performance; 2025 guidance unchanged Alphavalue
07/05/25 DiaSorin: Slight Q1 beat with 2025 guidance remaining unchanged Alphavalue
10/04/25 Kepler Cheuvreux Upgrades DiaSorin to Hold, Boosts PT MT
17/03/25 DiaSorin: Slight Q4 miss but the 2025 outlook was encouraging Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+1.77%
+7.65%
+31.15%
+0.87%
+54.63%
+47.91%
-11.29%
+26.91%
- +53.56%
Average +23.68%
Weighted average by Cap. +19.76%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
68.50EUR
Average target price
69.72EUR
Spread / Average Target
+1.77%
High Price Target
81.30EUR
Spread / Highest target
+18.69%
Low Price Target
58.00EUR
Spread / Lowest Target
-15.33%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Piper Sandler & Co.
alphavalue Anas Patel
UBS
Invest Securities
Mediobanca
Equita SIM
AlphaValue/Baader Europe
Intesa Sanpaolo
Deutsche Bank Research
Banca Akros (ESN)
JPMorgan
Morgan Stanley
RBC Capital Markets
Kepler Cheuvreux
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
68.50EUR
Average target price
69.72EUR
Spread / Average Target
+1.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DIA Stock
  4. Consensus DiaSorin S.p.A.
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!